Category: Engitix

  • Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

    Shots: Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. […]